Baird analyst David Rescott raised the firm’s price target on TransMedics (TMDX) to $152 from $148 and keeps an Outperform rating on the shares. The firm updated its model following results which continues to suggest it remains a best in class growth story.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Reports Strong Q2 2025 Financial Results
- TransMedics Group: Strong Financial Performance and Optimistic Outlook Justify Buy Rating
- TransMedics reports Q2 EPS 92c vs. 35c last year
- TransMedics raises FY25 revenue view to $585M-$605M from $565M-$585M
- Buy Rating for TransMedics Group Amid Strong Q2 Prospects and Seasonal Challenges